Paysign Achieves Record 2025 Financials, Projects Strong Double-Digit Growth for 2026

summarizeSummary

Paysign, Inc. announced record financial results for fiscal year 2025, with significant revenue and profit growth, and issued strong guidance for 2026, projecting continued double-digit expansion.

check_boxKey Events

• Record Full-Year 2025 Performance

  Total revenues increased 40.5% to $82.0 million, net income nearly doubled to $7.55 million ($0.13 per diluted share), and Adjusted EBITDA grew 107.3% to $19.94 million.

• Robust 2026 Financial Outlook

  The company projects full-year 2026 revenue of $106.5 million to $110.5 million (30-35% year-over-year growth) and net income of $13.0 million to $16.0 million ($0.21-$0.26 per diluted share), nearly doubling 2025 results.

• Growth Driven by Patient Affordability

  Pharma industry revenue surged 167.8% to $33.89 million, with 55 net patient affordability programs added during 2025, becoming a primary driver of growth and profitability.

• Strong Balance Sheet and Share Repurchase

  Paysign exited 2025 with $21.07 million in unrestricted cash and zero debt, while repurchasing 100,000 shares of common stock for $376 thousand.

auto_awesomeAnalysis

Paysign, Inc. delivered exceptional financial results for fiscal year 2025, driven by significant growth in its patient affordability offerings. The company reported a substantial 40.5% increase in full-year revenue and nearly doubled its net income and Adjusted EBITDA. Management provided robust guidance for 2026, projecting continued strong double-digit revenue growth of 30-35% and a further doubling of net income, signaling strong operational momentum and market demand for its specialized payment solutions. The company also strengthened its balance sheet, ending the year with zero debt and repurchasing shares, underscoring financial health and confidence in future prospects.